Diligence memo · auto-generated · as of July 2, 2026
Kanvas Biosciences, Inc.
Kanvas Biosciences, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Kanvas Biosciences, Inc. operates in Biotech / Pharma, based in MONMOUTH JUNCTION.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kanvas Biosciences, Inc. has raised $16M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2023-06-01.
Most recent recorded round closed around 2024-03-04.
Valuation (modeled)modeled
Provath models Kanvas Biosciences, Inc. at approximately $24M (range $4.4M–$55M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 3.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 70% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.